Investors are worried Novo Nordisk's competition with Eli Lilly is heating up and that the first-to-market GLP-1 leader is ...

Investors are worried Novo Nordisk's competition with Eli Lilly is heating up and that the first-to-market GLP-1 leader is ...

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...

The apparent success — and now almost ever-present ubiquity — of GLP-1 receptor agonists in weight loss has led to research, and possible uses, far beyond its initial indications in diabetes, ...

Novo Nordisk A/S NVO reported first-quarter 2025 earnings of 92 cents per American Depositary Receipt (ADR), which matched ...

Novo Nordisk A/S Data across obesity, cardiovascular disease, MASH, type 2 diabetes, as well as advances in obesity-related ...

Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more ...

A phase 3 trial shows that once-weekly semaglutide significantly improves liver histology in patients with metabolic ...

Prior to starting the trial, the participants also had moderate to high levels of scar tissue in the liver, known as stage 2 ...

Researchers say semaglutide, the medication in Ozempic and Wegovy, may help reverse MASH, a progressive liver condition ...

Patients either got a weekly 2.4 milligram dose of semaglutide, the active ingredient ... “These findings represent a very promising step forward in the fight against a common, progressive ...

Semaglutide and related weight-loss medications, known as GLP-1 agonists, may slow biological ageing, reduce inflammation, improve cognitive function and gut health, and reduce alcohol use in people ...